electroCore, Inc.
ECOR
View Detailed Chart
5.450USD
+0.380+7.50%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
41.61MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+7.50%
5 Days
-18.17%
1 Month
+11.91%
6 Months
-21.36%
Year to Date
+21.52%
1 Year
-65.87%
View Detailed Chart
TradingKey Stock Score of electroCore, Inc.
Currency: USD Updated: 2026-02-06Key Insights
electroCore, Inc.'s fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 92 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 19.68.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
electroCore, Inc.'s Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
electroCore, Inc. Highlights
StrengthsRisks
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 193.09% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 25.18M.
Fairly Valued
The company’s latest PE is -3.20, at a medium 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 242.94K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.69.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
19.680
Target Price
+288.17%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
electroCore, Inc. News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
electroCore, Inc. Info
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
Ticker SymbolECOR
CompanyelectroCore, Inc.
CEOGoldberger (Daniel S)
Websitehttps://www.electrocore.com/
Related Instruments
+3.02%
+0.09%
+1.60%
+2.48%
+0.40%
-1.14%
-0.05%
-2.35%
-1.76%
+2.65%
+2.64%
+2.03%
+2.01%
+2.38%
+1.70%
+0.16%
+0.78%
+1.72%
+0.59%
-2.02%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
70090.660
+120.530 (+0.17%)
282.580
+22.390 (+8.61%)
2081.160
+29.430 (+1.43%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
